Imperial College London

ProfessorPatrickSerruys

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.serruys

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Publication Type
Year
to

926 results found

Daemen J, Kukreja N, van Twisk P-H, Onuma Y, de Jaegere PPT, van Domburg R, Serruys PWet al., 2008, Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital registry, AMERICAN JOURNAL OF CARDIOLOGY, Vol: 101, Pages: 1105-1111, ISSN: 0002-9149

Journal article

Cheng C, Tempel D, Oostlander A, Helderman F, Gijsen F, Wentzel J, van Haperen R, Haitsma DB, Serruys PW, van der Steen AFW, de Crom R, Krams Ret al., 2008, Rapamycin modulates the eNOS vs. shear stress relationship, CARDIOVASCULAR RESEARCH, Vol: 78, Pages: 123-129, ISSN: 0008-6363

Journal article

Pedersen SS, Denollet J, van Gestel YRBM, Serruys PW, van Domburg RTet al., 2008, Clustering of psychosocial risk factors enhances the risk of depressive symptoms 12-months post percutaneous coronary intervention, EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, Vol: 15, Pages: 203-209, ISSN: 1741-8267

Journal article

Ramcharitar S, Serruys PW, 2008, Biodegradable stents., Minerva Cardioangiol, Vol: 56, Pages: 205-213, ISSN: 0026-4725

Bioabsorbable stents must be biocompatible and as well as their degenerated products. The challenge is to find material that exhibit minimal recoil and remain in situ for several months before complete bio-absorption. There are now some worthy polymer based and metallic bioabsorbable stents with encouraging preclinical and clinical data. Their behaviour will not only redefine current percutaneous coronary intervention but may also have a wider role in the cardiovascular system as whole.

Journal article

Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MWI, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof Set al., 2008, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, LANCET, Vol: 371, Pages: 899-907, ISSN: 0140-6736

Journal article

Ramcharitar S, Patterson MS, van Geuns RJ, van Meighem C, Serruys PWet al., 2008, Technology insight: magnetic navigation in coronary interventions, NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, Vol: 5, Pages: 148-156, ISSN: 1743-4297

Journal article

Hoffmann R, Morice M-C, Moses JW, Fitzgerald PJ, Mauri L, Breithardt G, Schofer J, Serruys PW, Stoll H-P, Leon MBet al., 2008, Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials, HEART, Vol: 94, Pages: 322-328, ISSN: 1355-6037

Journal article

Onuma Y, Müller R, Ramcharitar S, van Geuns R-JM, Louvard Y, Morel M-A, Morice M-C, Davis R, Kaplan AV, Lefèvre T, Grube E, Serruys PWet al., 2008, Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions., EuroIntervention, Vol: 3, Pages: 546-552, ISSN: 1774-024X

AIM: To report clinical and angiographic follow-up at 6 months after implantation of the Tryton Side-Branch Stent dedicated to bifurcation, in conjunction with standard workhorse drug-eluting stent (DES). METHODS AND RESULTS: Patients having angina or silent myocardial ischaemia with de novo bifurcation lesions were enrolled at three sites. The Tryton stent was first placed in the side-branch and a standard DES subsequently implanted in the main-branch. The primary endpoint was freedom from in-hospital major adverse cardiac events (MACE) following procedural success. Angiographic and clinical follow-up was performed at 6-months. Quantitative coronary angiography (QCA) was analysed with a new dedicated bifurcation software. Thirty patients were enrolled. At six months clinical follow-up was available in 100% with angiographic follow-up performed in 78%. The primary endpoint was met in 93.3%. The MACE rate at 6 months was 9.9%. QCA analysis demonstrated late luminal loss of 0.17 mm with no restenosis in the side branch. CONCLUSIONS: In conjunction with a workhorse DES to treat bifurcation lesions, the Tryton side-branch stent demonstrated acceptable clinical outcome and low side-branch late loss at six months.

Journal article

Serruys PW, 2008, The challenge of innovation: lost opportunities and new and uncharted futures., EuroIntervention, Vol: 3, ISSN: 1774-024X

Journal article

Khattab AA, Richardt G, Verin V, Kelbaek H, Macaya C, Berland J, Miquel-Hebert K, Dorange C, Serruys PWet al., 2008, Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial., EuroIntervention, Vol: 3, Pages: 566-573, ISSN: 1774-024X

AIMS: Restenosis is higher among certain subpopulations when subjected to percutaneous coronary interventions even when using drug-eluting stents. The randomised SPIRIT II trial demonstrated the superiority of the XIENCE V Everolimus Eluting Coronary Stent System over the TAXUS Paclitaxel-Eluting Stent System in terms of in-stent late loss at six months among 300 patients treated for de novo native coronary artery lesions. METHODS AND RESULTS: In this post-hoc analysis of SPIRIT II we focused on six-month angiographic outcomes of diabetic patients (n=69), left anterior descending arteries (n=149), long lesions >20 mm (n=43), small vessels <3.0 mm (n=209) and type B2 and C lesions (n=233). In-stent late loss was consistently less among all subgroups when treated by everolimus-eluting stents compared to paclitaxel-eluting stents: diabetics 0.15+/-0.26 mm versus 0.39+/-0.34 mm, p=0.006; LAD 0.12+/-0.23 mm versus 0.44+/-0.37 mm, p<0.001; long lesions 0.13+/-0.26 mm versus 0.43+/-0.46 mm, p=0.070; small vessels 0.17+/-0.28 mm versus 0.37+/-0.39 mm, p<0.001; B2/C lesions 0.12+/-0.31 mm versus 0.36+/-0.36 mm, p<0.001. CONCLUSION: The everolimus-eluting stent remained superior in terms of in-stent late loss in a variety of higher risk populations for restenosis compared to the paclitaxel-eluting stent. These analyses were consistent with the in-stent late loss results of the overall SPIRIT II trial population.

Journal article

Serruys PW, Vranckx P, Slagboom T, Regar E, Meliga E, de Winter RJ, Heyndrickx G, Schuler G, van Remortel EA, Dubé GP, Symons Jet al., 2008, Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD., EuroIntervention, Vol: 3, Pages: 600-609, ISSN: 1774-024X

AIMS: Haemoglobin based oxygen carriers (HBOCs) are considered in the treatment of patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In light of their potential vasopressor and colloidal properties, their effect on coronary physiology, safety and tolerability needs to be established. METHODS AND RESULTS: In this phase II pilot trial, 45 patients were randomly assigned, (1:1:1) to double blind treatment with a 30 minute intravenous (IV) infusion of either 15 or 30 g of HBOC-201, compared to an equivalent volume of non-oxygen carrier colloid control. Systemic, pulmonary, and coronary haemodynamics were studied during this infusion period. IV HBOC-201 administration produced an increase in systolic blood pressure (SBP), pulmonary capillary wedge pressure and calculated systemic vascular resistance (SVR) and a concomitant decrease in cardiac output (CO); there was a decrease in mixed venous saturation (SVO2) following IV HBOC-201. The left ventricular stroke work index (LVSWI) was not altered by HBOC-201 treatment. Of note, no coronary vasoconstriction was observed, nor were there significant changes in resting average peak velocity (APV), coronary-artery diameter, volumetric coronary blood flow, or coronary vascular resistance. The percentage of patients with adverse events did not differ between the HBOC-201 treated and control groups (76% vs. 63%, respectively, P=0.49). Seven serious adverse events (SAE) occurred in six patients in the treatment group and two in two patients in the control group. Only one SAE (hypertension) was judged HBOC-201 related. Patients in both the HBOC-201 and control group had a similar incidence of increased liver alanine transaminase (31% vs 31%, respectively, NS); 10% of the patients in the HBOC-201 group had increases greater than three times the upper limit of normal. Differential increases were noticed in some inflammatory markers (IL-6, CRP) 18-24 hours after infusion between the HBOC-2

Journal article

van Mieghem C, Ramcharitar S, Barlis P, Oosterhuis W, Kik C, de Feyter P, Serruys PWet al., 2008, Myocardial infarction in a patient with sickle cell trait. Treatment dilemmas and imaging findings at follow-up., EuroIntervention, Vol: 3, Pages: 627-634, ISSN: 1774-024X

BACKGROUND: A 43-year-old woman with a 2-hour history of chest pain presented with an anterior infarction and was referred for primary percutaneous coronary intervention. INVESTIGATIONS: Physical examination, electrocardiography, laboratory tests, coronary angiography, abdominal angiography, cardiac CT, histology, immunohistochemistry, intravascular ultrasound. DIAGNOSIS: ST-segment elevation anterior myocardial infarction. MANAGEMENT: Coronary angiography, antithrombotic therapy, statin, angiotensin-converting enzyme inhibitor, thrombectomy, coronary artery bypass graft surgery.

Journal article

Kukreja N, Onuma Y, Daemen J, Serruys PWet al., 2008, The future of drug-eluting stents., Pharmacol Res, Vol: 57, Pages: 171-180, ISSN: 1043-6618

This review aims to provide a glimpse into the future of drug-eluting stents (DES). Since their arrival in 2002, DES have transformed the practice of interventional cardiology by drastically reducing restenosis and the need for repeat revascularization. However, data about the potentially fatal long-term risk of stent thrombosis have spurred on research and development to improve upon the first generation of devices. The initial commercially available DES used a stainless steel platform coated with a permanent polymer to provide controlled release of the anti-restenotic drug. The platform, polymer and drug are all targets for improvement. More advanced metallic and fully biodegradable stent platforms are currently under investigation. The permanent polymer coating, a likely contributor adverse events, is being superseded by biocompatible and bioabsorbable alternatives. New drugs and drug combinations are also a research goal, as interventional cardiologists and the industry strive towards safer anti-restenotic DES.

Journal article

Ramcharitar S, Onuma Y, Aben J-P, Consten C, Weijers B, Morel M-A, Serruys PWet al., 2008, A novel dedicated quantitative coronary analysis methodology for bifurcation lesions., EuroIntervention, Vol: 3, Pages: 553-557, ISSN: 1774-024X

AIMS: To develop a novel dedicated quantitative coronary analysis (QCA) for bifurcations. METHOD AND RESULTS: A dedicated software that has minimal user interaction so as to increase the QCA results reproducibility. The new CAAS 5 bifurcation software combines established algorithm for contour detection with novel ways to determine the lesion characteristics together with the angulation of the bifurcation. CONCLUSION: The paper describes how this methodology is accomplished and reported.

Journal article

Kukreja N, Serruys PW, 2008, When is percutaneous coronary intervention a better choice than coronary artery by-pass grafting?, Pol Arch Med Wewn, Vol: 118, Pages: 98-99

Journal article

Denollet J, Pedersen SS, Daemen J, de Jaegere P, Serruys PW, van Domburg RTet al., 2008, Reduced positive affect (anhedonia) predicts major clinical events following implantation of coronary-artery stents, JOURNAL OF INTERNAL MEDICINE, Vol: 263, Pages: 203-211, ISSN: 0954-6820

Journal article

García-García HM, Gonzalo N, Granada JF, Regar E, Serruys PWet al., 2008, Diagnosis and treatment of coronary vulnerable plaques., Expert Rev Cardiovasc Ther, Vol: 6, Pages: 209-222

Thin-capped fibroatheroma is the morphology that most resembles plaque rupture. Detection of these vulnerable plaques in vivo is essential to being able to study their natural history and evaluate potential treatment modalities and, therefore, may ultimately have an important impact on the prevention of acute myocardial infarction and death. Currently, conventional grayscale intravascular ultrasound, virtual histology and palpography data are being collected with the same catheter during the same pullback. A combination of this catheter with either thermography capability or additional imaging, such as optical coherence tomography or spectroscopy, would be an exciting development. Intravascular magnetic resonance imaging also holds much promise. To date, none of the techniques described above have been sufficiently validated and, most importantly, their predictive value for adverse cardiac events remains elusive. Very rigorous and well-designed studies are compelling for defining the role of each diagnostic modality. Until we are able to detect in vivo vulnerable plaques accurately, no specific treatment is warranted.

Journal article

Serruys PWJC, van Geuns R-J, 2008, Arguments for recanalization of chronic total occlusions., JACC Cardiovasc Interv, Vol: 1, Pages: 54-55

Journal article

Kirschbaum SW, Baks T, van den Ent M, Sianos G, Krestin GP, Serruys PW, de Feyter PJ, van Geuns R-JMet al., 2008, Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions, AMERICAN JOURNAL OF CARDIOLOGY, Vol: 101, Pages: 179-185, ISSN: 0002-9149

Journal article

Ramcharitar S, Daeman J, Patterson M, van Guens RJ, Boersma E, Serruys PW, van der Giessen WJet al., 2008, First direct in vivo comparison of two commercially available three-dimensional quantitative coronary angiography systems, CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol: 71, Pages: 44-50, ISSN: 1522-1946

Journal article

Ramcharitar S, Serruys PW, 2008, Fully Biodegradable Coronary Stents Progress to Date, AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, Vol: 8, Pages: 305-314, ISSN: 1175-3277

Journal article

Ramcharitar S, Hochadel M, Gaster AL, Onuma Y, Gitt A, Serruys PWet al., 2008, An insight into the current use of drug eluting stents in acute and elective percutaneous coronary interventions in Europe. A report on the EuroPCI Survey., EuroIntervention, Vol: 3, Pages: 429-441, ISSN: 1774-024X

AIMS: To assess the use of drug eluting stents (DES) and passive stents in patients undergoing percutaneous coronary interventions (PCI) in Europe. METHODS AND RESULTS: We looked at the characteristics, procedural details and immediate outcome of 9,380 patients consisting of 2,471 STEMI patients (26.3%), 1,752 patients with NSTEMI-ACS (18.7%), and 5,157 elective patients (55.0%) in the European Heart Survey. The hybrid population of DES and passive stented patients (506 patients), and those treated without a stent, were excluded from the direct comparison between the two stented subgroup. These patients were, however, included in the total treated PCI population consisting of 10,982 patients. Patients presenting with stable angina or NSTEMI-ACS were more often treated with DES than patients with STEMI, which was in accordance with the current European Society of Cardiology (ESC) guidelines. There was no excess of acute stent thrombosis in the DES treated patients in any clinical setting including STEMI. Periprocedural complications were less in STEMI patients treated with DES compared to passive stents (BMS or coated stents). More complicated lesions and off-label use was observed with DES than passive stents. The overall in-hospital mortality was low (1.8%) and was better in the DES (1.2%) than passive stented patients (2.1%). In-hospital MACCE for the total PCI population (N=10,982) reflected the clinical presentation as it increased from electives (1.4%), NSTEMI-ACS (6.4%) to STEMI (7.8%) patients. CONCLUSIONS: There is marked variability in DES use across Europe. More detailed studies are needed to address the outcome of DES, especially in STEMI patients and the off-label use in order to contemplate a revision of the current ESC guidelines.

Journal article

Serruys PW, 2008, Taking the "measure" of a profession., EuroIntervention, Vol: 3, ISSN: 1774-024X

Journal article

van Domburg RT, Daemen J, Pedersen SS, Bressers M, van Herwerden LA, Firth BG, Unger F, Serruys PWet al., 2008, Short- and long- term health related quality-of-life and anginal status after randomisation to coronary stenting versus bypass surgery for the treatment of multivessel disease: results of the Arterial Revascularisation Therapy Study (ARTS)., EuroIntervention, Vol: 3, Pages: 506-511, ISSN: 1774-024X

BACKGROUND: Health related quality-of-life (HRQL) beyond one year of treatment of multivessel coronary artery disease with stenting or coronary artery bypass grafting (CABG) is yet unknown. The Arterial Revascularisation Therapy Study (ARTS) was designed to compare CABG and stenting in multivessel disease. METHODS AND RESULTS: HRQL was evaluated at baseline, at 1- month and at 6-, 12- and 36 months after revascularisation using the Short Form Health Survey (SF-36) in patients randomised to stenting (n=483) versus CABG (n=492). Both stenting and CABG resulted in significant improvement of HRQL and anginal status. Although there was a trend for better HRQL after CABG up to one year, the disparity between the two procedures decreased long-term. Most of the difference between the two procedures was attributed to repeat interventions in the stent group; at three years, 19% of stent patients versus 13% of CABG patients (p<0.0001) had undergone a repeat intervention. On most of the SF-36 scores, there was no difference between diabetics and non-diabetics, with diabetic patients having a worse score only on general health and physical functioning at all time points (p<0.0001). CONCLUSIONS: Both stenting and CABG resulted in a significant improvement in HRQL especially up to one year, but CABG was associated with less angina at all time points. There was a trend for better HRQL after CABG, but this difference was mainly attributed to repeat revascularisation in the stent group. Based on these findings, patients should select for themselves whether or not they would prefer the improved HRQL benefits after CABG, or whether they would prefer more angina after PCI and avoid a major operation.

Journal article

Serruys PW, Daemen J, Morice M-C, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins KD, Vranckx P, Bressers M, van Domburg R, Schuijer M, Wittebols K, Pieters M, Stoll HPet al., 2008, Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease., EuroIntervention, Vol: 3, Pages: 450-459, ISSN: 1774-024X

AIMS: Late stent thrombosis has been documented in on- and off-label populations. Stent thrombosis is more frequently in higher risk patients and there is still scarce data about the impact on late adverse cardiac events. The aim therefore is to determine the 3-year safety and effectiveness of Sirolimus-Eluting Stent (SES) (Cypher(R)) implantation in patients with multivessel disease and to compare outcomes with the historical results of the two arms of the Arterial Revascularisation Therapies Study (ARTS-I). METHODS AND RESULTS: ARTS-II is a 45 centre, 607 patient single-arm study. Three years outcomes were compared to the outcome of the historical cohorts of ARTS-I using the same inclusion and exclusion criteria and major adverse cardiac and cerebrovascular events (MACCE) definitions. Patients were stratified by clinical site to ensure that at least 1/3 had 3-vessel disease to achieve a number of treated lesions per patient comparable to ARTS-I. Stent thrombosis was re-adjudicated using the ARC definitions. An angiographic coronary score to characterise lesion complexity was applied to allow the identification of patients who might benefit the most from multivessel stenting. In ARTS-II, 46.6% of the patients underwent 3-vessel treatment as compared to 18.0% in ARTS-I percutaneous coronary intervention (PCI) (n=600) with bare metal stents (BMS). Diabetes was present in 26.2% in ARTS-II as compared to 17.3% in ARTS-I. In ARTS-II, patients received on average 3.7 stents resulting in a mean total stented length of 72.5 mm. The 3-year survival rate in ARTS-II was 97.0%, comparable to the 95.6% and 96.0% of the historical surgical (n=605) and PCI cohorts of ARTS-I. The death/cerebrovascular accident (CVA)/myocardial infarction (MI) event free survival rate in ARTS-II was 91.7%, versus 89.1% (p=0.1) and 87.2% (p=0.007) in ARTS-I coronary artery bypass graft (CABG) and PCI cohorts, respectively. Freedom from revascularisation in ARTS-II was 85.5%, lower than in ARTS-I CAB

Journal article

García-García HM, Gonzalo N, Tanimoto S, Meliga E, de Jaegere P, Serruys PWet al., 2008, Characterization of Edge Effects With Paclitaxel-Eluting Stents Using Serial Intravascular Ultrasound Radiofrequency Data Analysis: The BETAX (BEside TAXus) Study., Rev Esp Cardiol (Engl Ed), Vol: 61, Pages: 1013-1019

At present, the effect of paclitaxel on tissue structure at the edges of Taxus® stents is unknown. The objective of this study was to investigate in vivo the temporal changes occurring at the edges of paclitaxel-eluting stents using intravascular ultrasound radiofrequency (IVUS-RF) data analysis.

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00712243&limit=30&person=true&page=31&respub-action=search.html